167 related articles for article (PubMed ID: 38506770)
1. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.
Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF
Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation for engraftment of CD34
Uchida N; Li L; Nassehi T; Drysdale CM; Yapundich M; Gamer J; Haro-Mora JJ; Demirci S; Leonard A; Bonifacino AC; Krouse AE; Linde NS; Allen C; Peshwa MV; De Ravin SS; Donahue RE; Malech HL; Tisdale JF
Cell Rep Med; 2021 Apr; 2(4):100247. PubMed ID: 33948577
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic base editing of human hematopoietic stem cells.
Zeng J; Wu Y; Ren C; Bonanno J; Shen AH; Shea D; Gehrke JM; Clement K; Luk K; Yao Q; Kim R; Wolfe SA; Manis JP; Pinello L; Joung JK; Bauer DE
Nat Med; 2020 Apr; 26(4):535-541. PubMed ID: 32284612
[TBL] [Abstract][Full Text] [Related]
4. BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity.
Demirci S; Zeng J; Wu Y; Uchida N; Shen AH; Pellin D; Gamer J; Yapundich M; Drysdale C; Bonanno J; Bonifacino AC; Krouse AE; Linde NS; Engels T; Donahue RE; Haro-Mora JJ; Leonard A; Nassehi T; Luk K; Porter SN; Lazzarotto CR; Tsai SQ; Weiss MJ; Pruett-Miller SM; Wolfe SA; Bauer DE; Tisdale JF
J Clin Invest; 2020 Dec; 130(12):6677-6687. PubMed ID: 32897878
[TBL] [Abstract][Full Text] [Related]
5. Chemical Modification of Guide RNAs for Improved CRISPR Activity in CD34+ Human Hematopoietic Stem and Progenitor Cells.
Shapiro J; Tovin A; Iancu O; Allen D; Hendel A
Methods Mol Biol; 2021; 2162():37-48. PubMed ID: 32926376
[TBL] [Abstract][Full Text] [Related]
6. Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates.
Humbert O; Radtke S; Samuelson C; Carrillo RR; Perez AM; Reddy SS; Lux C; Pattabhi S; Schefter LE; Negre O; Lee CM; Bao G; Adair JE; Peterson CW; Rawlings DJ; Scharenberg AM; Kiem HP
Sci Transl Med; 2019 Jul; 11(503):. PubMed ID: 31366580
[TBL] [Abstract][Full Text] [Related]
7. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
[TBL] [Abstract][Full Text] [Related]
9. The CCR5 Gene Edited CD34
Karuppusamy KV; Demosthenes JP; Venkatesan V; Christopher AC; Babu P; Azhagiri MK; Jacob A; Ramalingam VV; Rangaraj S; Murugesan MK; Marepally SK; Varghese GM; Srivastava A; Kannangai R; Thangavel S
Front Immunol; 2022; 13():792684. PubMed ID: 35359982
[TBL] [Abstract][Full Text] [Related]
10. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
[TBL] [Abstract][Full Text] [Related]
11. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.
Métais JY; Doerfler PA; Mayuranathan T; Bauer DE; Fowler SC; Hsieh MM; Katta V; Keriwala S; Lazzarotto CR; Luk K; Neel MD; Perry SS; Peters ST; Porter SN; Ryu BY; Sharma A; Shea D; Tisdale JF; Uchida N; Wolfe SA; Woodard KJ; Wu Y; Yao Y; Zeng J; Pruett-Miller S; Tsai SQ; Weiss MJ
Blood Adv; 2019 Nov; 3(21):3379-3392. PubMed ID: 31698466
[TBL] [Abstract][Full Text] [Related]
12. Base editing of haematopoietic stem cells rescues sickle cell disease in mice.
Newby GA; Yen JS; Woodard KJ; Mayuranathan T; Lazzarotto CR; Li Y; Sheppard-Tillman H; Porter SN; Yao Y; Mayberry K; Everette KA; Jang Y; Podracky CJ; Thaman E; Lechauve C; Sharma A; Henderson JM; Richter MF; Zhao KT; Miller SM; Wang T; Koblan LW; McCaffrey AP; Tisdale JF; Kalfa TA; Pruett-Miller SM; Tsai SQ; Weiss MJ; Liu DR
Nature; 2021 Jul; 595(7866):295-302. PubMed ID: 34079130
[TBL] [Abstract][Full Text] [Related]
13. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
Wen J; Tao W; Hao S; Zu Y
J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Engraftment and Fetal Globin Induction upon
Chang KH; Smith SE; Sullivan T; Chen K; Zhou Q; West JA; Liu M; Liu Y; Vieira BF; Sun C; Hong VP; Zhang M; Yang X; Reik A; Urnov FD; Rebar EJ; Holmes MC; Danos O; Jiang H; Tan S
Mol Ther Methods Clin Dev; 2017 Mar; 4():137-148. PubMed ID: 28344999
[TBL] [Abstract][Full Text] [Related]
16. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Locatelli F; Lang P; Wall D; Meisel R; Corbacioglu S; Li AM; de la Fuente J; Shah AJ; Carpenter B; Kwiatkowski JL; Mapara M; Liem RI; Cappellini MD; Algeri M; Kattamis A; Sheth S; Grupp S; Handgretinger R; Kohli P; Shi D; Ross L; Bobruff Y; Simard C; Zhang L; Morrow PK; Hobbs WE; Frangoul H;
N Engl J Med; 2024 May; 390(18):1663-1676. PubMed ID: 38657265
[TBL] [Abstract][Full Text] [Related]
17. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications.
Venkatesan V; Christopher AC; Karuppusamy KV; Babu P; Alagiri MKK; Thangavel S
J Vis Exp; 2022 Aug; (186):. PubMed ID: 36036597
[TBL] [Abstract][Full Text] [Related]
19. TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells.
Yen J; Fiorino M; Liu Y; Paula S; Clarkson S; Quinn L; Tschantz WR; Klock H; Guo N; Russ C; Yu VWC; Mickanin C; Stevenson SC; Lee C; Yang Y
Sci Rep; 2018 Nov; 8(1):16304. PubMed ID: 30389991
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 Editing of the
Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL
N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
